266 related articles for article (PubMed ID: 17130524)
21. [Angiogenic effect of interleukin-8 in breast cancer and its association with estrogen receptor].
Lin Y; Wang SM; Huang RP
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1419-23. PubMed ID: 16029657
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and mechanism of action of 1alpha-hydroxy-24-ethyl-cholecalciferol (1alpha[OH]D5) in breast cancer prevention and therapy.
Hussain EA; Mehta RR; Ray R; Das Gupta TK; Mehta RG
Recent Results Cancer Res; 2003; 164():393-411. PubMed ID: 12899538
[TBL] [Abstract][Full Text] [Related]
23. Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer.
Friedrich M; Villena-Heinsen C; Tilgen W; Schmidt W; Reichrat J; Axt-Fliedner R
Anticancer Res; 2002; 22(3):1919-24. PubMed ID: 12168894
[TBL] [Abstract][Full Text] [Related]
24. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the human vitamin D3 receptor promoter in breast cancer cells is mediated through Sp1 sites.
Wietzke JA; Ward EC; Schneider J; Welsh J
Mol Cell Endocrinol; 2005 Jan; 230(1-2):59-68. PubMed ID: 15664452
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells.
Gommersall LM; Khanim FL; Peehl DM; Doherty AH; Campbell MJ
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):251-6. PubMed ID: 15225780
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.
Ting HJ; Bao BY; Reeder JE; Messing EM; Lee YF
Mol Cancer Res; 2007 Sep; 5(9):967-80. PubMed ID: 17855664
[TBL] [Abstract][Full Text] [Related]
28. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.
Essa S; Reichrath S; Mahlknecht U; Montenarh M; Vogt T; Reichrath J
Anticancer Res; 2012 Jan; 32(1):383-9. PubMed ID: 22213330
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic corruption of VDR signalling in malignancy.
Abedin SA; Banwell CM; Colston KW; Carlberg C; Campbell MJ
Anticancer Res; 2006; 26(4A):2557-66. PubMed ID: 16886664
[TBL] [Abstract][Full Text] [Related]
30. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
Liu ZJ; Zhu BT
J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420
[TBL] [Abstract][Full Text] [Related]
31. Stimulation of estrogen receptor signaling by gamma synuclein.
Jiang Y; Liu YE; Lu A; Gupta A; Goldberg ID; Liu J; Shi YE
Cancer Res; 2003 Jul; 63(14):3899-903. PubMed ID: 12873981
[TBL] [Abstract][Full Text] [Related]
32. Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors.
Banwell CM; O'Neill LP; Uskokovic MR; Campbell MJ
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):245-9. PubMed ID: 15225779
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: implications for therapeutics.
Seubwai W; Wongkham C; Puapairoj A; Khuntikeo N; Wongkham S
Cancer; 2007 Jun; 109(12):2497-505. PubMed ID: 17487855
[TBL] [Abstract][Full Text] [Related]
34. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells.
Freund A; Chauveau C; Brouillet JP; Lucas A; Lacroix M; Licznar A; Vignon F; Lazennec G
Oncogene; 2003 Jan; 22(2):256-65. PubMed ID: 12527894
[TBL] [Abstract][Full Text] [Related]
35. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.
Journe F; Laurent G; Chaboteaux C; Nonclercq D; Durbecq V; Larsimont D; Body JJ
Breast Cancer Res Treat; 2008 Jan; 107(1):49-61. PubMed ID: 17333335
[TBL] [Abstract][Full Text] [Related]
36. Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells.
Peng X; Mehta R; Wang S; Chellappan S; Mehta RG
Cancer Res; 2006 Jul; 66(14):7361-9. PubMed ID: 16849588
[TBL] [Abstract][Full Text] [Related]
37. The genes of the coactivator TIF2 and the corepressor SMRT are primary 1alpha,25(OH)2D3 targets.
Dunlop TW; Väisänen S; Frank C; Carlberg C
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):257-60. PubMed ID: 15225781
[TBL] [Abstract][Full Text] [Related]
38. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells.
Philips A; Teyssier C; Galtier F; Rivier-Covas C; Rey JM; Rochefort H; Chalbos D
Mol Endocrinol; 1998 Jul; 12(7):973-85. PubMed ID: 9658402
[TBL] [Abstract][Full Text] [Related]
39. Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements.
Swami S; Krishnan AV; Peng L; Lundqvist J; Feldman D
Endocr Relat Cancer; 2013 Aug; 20(4):565-77. PubMed ID: 23744764
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma.
Villena-Heinsen C; Meyberg R; Axt-Fliedner R; Reitnauer K; Reichrath J; Friedrich M
Anticancer Res; 2002; 22(4):2261-7. PubMed ID: 12174912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
